Comparison between an SGLT2 inhibitor and insulin in tumor-to-tissue contrasts in 18F-FDG PET imaging of diabetic mice
Open Access
- 26 October 2023
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-8
Abstract
18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) has been widely utilized for tumor diagnosis. Hyperglycemia affects the 18F-FDG uptake and reduces tumor-to-tissue contrasts, however, ideal hypoglycemic drugs are lacking. This study compared the role of insulin with the novel widely used hypoglycemic drug, sodium-glucose cotransporter 2 (SGLT2) inhibitor, on 18F-FDG PET imaging in diabetic conditions. The streptozotocin (STZ)-induced diabetic C57BL/6N mice were inoculated with B16 (mouse melanoma) cells to establish the xenograft tumor model. After the mice had been administrated with dapagliflozin (30 mg/kg, IG) or insulin (0.75 U/kg, IP) for one hour, 9.25 MBq/10 g 18F-FDG was injected. Biodistributions were detected by gamma counting and microPET imaging. The results showed dapagliflozin did not significantly affect the 18F-FDG uptake in tumors but reduced uptake in reference tissues, resulting in a significant increase in the tumor-to-skeletal muscle ratio. Conversely, insulin increased 18F-FDG uptake in tumors without significant reduction in uptake in reference tissues; Although there was an observable improvement in tumor imaging, it did not reach significantly statistical differences. This study suggests that insulin and SGLT2 inhibitor yield comparable effects on the quality of 18F-FDG PET imaging in diabetic patients. Nevertheless, SGLT2 inhibitors would be more suitable when skeletal muscle is used as reference tissue.Keywords
Funding Information
- CAMS Innovation Fund (2021-1-I2M-029)
- Natural Science Foundation of Beijing Municipality (7222119)
- Beijing TCM Science and Technology Foundation (JJ-2020-04)
- Interdisciplinary Clinical Research Project of Peking University First Hospital (2021CR32)
This publication has 40 references indexed in Scilit:
- Ultrashort-acting insulin may improve on 18F-FDG PET/CT image quality in patients with uncontrolled diabetic mellitusNuclear Medicine Communications, 2013
- A Comparison of Imaging Techniques to Monitor Tumor Growth and Cancer Progression in Living AnimalsInternational Journal of Molecular Imaging, 2011
- Insulin regulates GLUT1‐mediated glucose transport in MG‐63 human osteosarcoma cellsJournal of Cellular Physiology, 2011
- Comparison of the transcellular transport of FDG and D-glucose by the kidney epithelial cell line, LLC-PK1Nuclear Medicine Communications, 2010
- Impact of Intravenous Insulin on 18F-FDG PET in Diabetic Cancer PatientsJournal of Nuclear Medicine, 2009
- Immunohistochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesionsJournal of Experimental & Clinical Cancer Research, 2008
- The facilitative glucose transporter GLUT3: 20 years of distinctionAmerican Journal of Physiology-Endocrinology and Metabolism, 2008
- Kidney Modelling for FDG Excretion with PETInternational Journal of Biomedical Imaging, 2007
- Optimization of Whole-Body Positron Emission Tomography Imaging by Using Delayed 2-Deoxy-2-[F-18]fluoro-d-glucose Injection Following I.V. Insulin in Diabetic PatientsMolecular Imaging and Biology, 2006
- Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancerJournal of Cellular Physiology, 2004